Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We were delighted to learn from the announcement today, 6 May 2021, that Professor Fran Platt has been elected a Fellow of The Royal Society. She is one of the 52 distinguished scientists whose election was announced, and one of the two biologists out of six Oxford academics so-honoured this year. https://royalsociety.org/news/2021/05/new-fellows-announcement-2021/

Professor Fran PlattFran is a biochemist and pharmacologist. She studies a group of rare genetic disorders called lysosomal storage diseases with a view to developing new drug therapies. The lysosome, a compartment inside cells, is responsible for breaking down big molecules. When the lysosome goes wrong molecules build up in the lysosome and this accumulation of material is called “storage”. Fran focuses on a subgroup of these diseases in which fatty molecules called sphingolipids are stored. These rare diseases mainly affect infants and children, but adults can also develop these disorders. They are all progressive in nature and most affect the brain leading to neurodegeneration.

Fran found that a drug she was studying as an anti-viral compound could be used to treat lysosomal diseases. Her research with colleagues in Oxford led to the approval of the drug miglustat for treating Gaucher disease and Niemann-Pick disease type C. She has also developed other drugs for treating these rare diseases that are currently in clinical trials. Fran’s research therefore spans basic science and translation.

We warmly congratulate Fran on this distinguished and well-deserved honour.

Fran commented “It’s a great honour to have been elected and I hope this will help raise awareness about the devastating diseases we work on. I am truly indebted to past and present members of my lab and our collaborators for their outstanding work over the years”. 

The Department of Pharmacology now has three Fellows of The Royal Society: Peter Somogyi, Antony Galione, and now Fran.

Similar stories

Emptage group successful with £1m MRC-AMED award

Congratulations to the group of Professor Nigel Emptage who have been awarded an MRC-AMED grant, worth £1m, in conjuction with the University of Tokyo and the RIKEN Center for Brain Science

Burton group wins image competition at Oxford BHF CRE Annual Symposium

This image of a blood clot composed of erythrocytes trapped by long fibrous chains of fibrin was judged the winner of the image competition at the BHF CRE 2022 Symposiium, held in December. In this image we can see false coloured erythrocytes (classic biconcave appearance around 5-10 µm in diameter) wrapped by fibrin network.

Understanding the brain at Didcot Girls School Science Club

A group of researchers and students led by Dr Tim Viney visited Didcot Girls School to run a ‘hands on’ event about the brain at the school’s Science Club.

Raised intracellular chloride levels underlie the effects of tiredness in cortex

The feeling of being tired is familiar to everyone. As we know from our own experience, an extended period of wakefulness results in a decline in our performance levels, and the desire to sleep becomes almost irresistible. When you then fall asleep, your sleep is deeper and more consolidated than usual. And yet after just one night of uninterrupted sleep, you can feel refreshed and “back to normal”!

Consequences of Tau pathology on hippocampal pyramidal neurons and network activity in ageing mice

Pathological hyperphosphorylated forms of the microtubule-associated binding protein Tau (pTau) are commonly found in people with neurodegenerative diseases, including Alzheimer’s disease, Corticobasal degeneration, and Progressive supranuclear palsy.